As An Oncology Therapeutics Companytelo Therapeuticsmission Is To Dramatically Improve Survival And Well Being In Cancer Patients Who Have Run Out Of Treatment Options Telo Therapeutics Is Focused On Developing Orally Bioavailable Next Generation Inhibitors Of Nuclear Transporta Critical Nexus Among Many Cancer Cell Signaling Pathwaysour Development Candidatetsm74Is A Novel Targeted Protein Degrader Of Xpo1A Clinically Validated Oncology Target Relevant To A Wide Range Of Solid And Hematological Cancerstsm74 Has A Dramatically Improved Safety Profile Compared To Existing Toxic Covalent Inhibitorsleading To Rapid Tumor Regressions And Complete Tumor Removal Across Multiple Preclinical Cancer Models
